Neoadjuvant PARP Inhibitor Scheduling in BRCA1 and BRCA2 Related Breast Cancer: PARTNER, a Randomized Phase II/III Trial

Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit DNA repair deficiency in germline BRCA1 and BRCA2 pathogenic variant (gBRCAm) cancers. Haematological toxicity limits chemotherapy-PARPi treatment combinations. In preclinical models we identified a schedule combining olaparib and carboplatin that avoids enhanced toxicity but maintains anti-tumour activity. We investigated this schedule in a neoadjuvant, phase II-III, randomised controlled …

Mastectomy, salpingo-oophorectomy improve BRCA breast cancer patient survival

By Lynda Williams, medwireNews ReportermedwireNews: Risk-reducing surgery leads to improved overall survival for breast cancer patients carrying a BRCA1 or BRCA2 mutation, confirm two studies published in The Lancet Oncology.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full story on the L’Institut Servier websiteImage credit: © Pradit_Ph / Getty Images / iStock The post Mast…